Aevi Genomic Medicine (NASDAQ: GNMX) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.
Risk & Volatility
Get Aevi Genomic Medicine alerts:Aevi Genomic Medicine has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.
Profitability
This table compares Aevi Genomic Medicine and ADMA Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aevi Genomic Medicine | N/A | -160.09% | -127.64% |
| ADMA Biologics | -101.93% | -88.31% | -25.76% |
Insider and Institutional Ownership
22.8% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 37.4% of ADMA Biologics shares are held by institutional investors. 11.7% of Aevi Genomic Medicine shares are held by company insiders. Comparatively, 16.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Aevi Genomic Medicine and ADMA Biologics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aevi Genomic Medicine | N/A | N/A | -$34.71 million | ($0.83) | -1.99 |
| ADMA Biologics | $22.76 million | 10.53 | -$43.75 million | ($1.91) | -2.77 |
Aevi Genomic Medicine has higher earnings, but lower revenue than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Aevi Genomic Medicine and ADMA Biologics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aevi Genomic Medicine | 0 | 1 | 1 | 0 | 2.50 |
| ADMA Biologics | 0 | 0 | 2 | 0 | 3.00 |
Aevi Genomic Medicine currently has a consensus price target of $4.25, suggesting a potential upside of 157.58%. ADMA Biologics has a consensus price target of $7.50, suggesting a potential upside of 41.78%. Given Aevi Genomic Medicine’s higher possible upside, equities analysts plainly believe Aevi Genomic Medicine is more favorable than ADMA Biologics.
Summary
ADMA Biologics beats Aevi Genomic Medicine on 8 of the 13 factors compared between the two stocks.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
No comments:
Post a Comment